- Increased efficacy with longer inter-dose interval
- Protection of over 70% starting after a first dose
- First indication of reduction in disease transmission of up to 67%
(PRESS RELEASE) CAMBRIDGE, 3-Feb-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced it confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials of its COVID-19 Vaccine AstraZeneca. The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19, with no severe cases and no hospitalisations, more than 22 days after the first dose.
Results demonstrated vaccine efficacy of 76% (CI: 59% to 86%) after a first dose, with protection maintained to the second dose. With an inter-dose interval of 12 weeks or more, vaccine efficacy increased to 82% (CI: 63%, 92%).
The analysis also showed the potential for the vaccine to reduce asymptomatic transmission of the virus, based on weekly swabs obtained from volunteers in the UK trial. The data showed that PCR positive readings were reduced by 67% (CI: 49%, 78%) after a single dose, and 50% (CI: 38% to 59%) after the two dose regimen, supporting a substantial impact on transmission of the virus.
The primary analysis for efficacy was based on 17,177 participants accruing 332 symptomatic cases from the Phase III UK (COV002), Brazil (COV003) and South Africa (COV005) trials led by Oxford University and AstraZeneca, a further 201 cases than previously reported.
Sir Mene Pangalos, Executive Vice President BioPharmaceuticals R&D, said: “This primary analysis reconfirms that our vaccine prevents severe disease and keeps people out of hospital. In addition, extending the dosing interval not only boosts the vaccine’s efficacy, but also enables more people to be vaccinated upfront. Together with the new findings on reduced transmission, we believe this vaccine will have a real impact on the pandemic.”
Professor Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial, and co-author of the paper, said: “These new data provide an important verification of the interim data that has helped regulators such as the MHRA in the UK and elsewhere around the world to grant the vaccine emergency use authorisation. It also helps to support the policy recommendation made by the Joint Committee on Vaccination and Immunisation for a 12-week prime-boost interval, as they look for the optimal approach to roll out, and reassures us that people are protected 22 days after a single dose of the vaccine.”
Data will continue to be analysed and shared with regulators around the world to support their ongoing rolling reviews for emergency supply or conditional approval during the health crisis. AstraZeneca is also seeking Emergency Use Listing from the World Health Organization for an accelerated pathway to vaccine availability in low-income countries.
The vaccine can be stored, transported and handled at normal refrigerated conditions (two-eight degrees Celsius/36-46 degrees Fahrenheit) for at least six months and administered within existing healthcare settings.
AstraZeneca continues to engage with governments, international organisations and collaborators around the world to ensure broad and equitable access to the vaccine at no profit for the duration of the pandemic.
COV002
COV002 is a single-blinded, multi-centre, randomised, controlled Phase II/III trial assessing the safety, efficacy and immunogenicity of AZD1222 in 12,390 participants in the UK. Trial participants to date are aged 18 years or over, who are healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus. Participants receive one or two intramuscular doses of a half dose (~2.5 x1010 viral particles) or full dose (~5×1010 viral particles) of AZD1222 or comparator, meningococcal vaccine MenACWY. Participants have blood samples drawn and clinical assessments for safety as well as immunogenicity at multiple timepoints up to one year post-vaccination. Suspected cases presenting with compatible symptoms were tested for virological confirmation by COVID-19 PCR. In addition, weekly swabbing are done for detection of infection and assessment of vaccine efficacy against infection.
COV003
COV003 is a single-blinded, multi-centre, randomised, controlled Phase III trial assessing the safety, efficacy, and immunogenicity of AZD1222 in 10,300 participants in Brazil. Trial participants to date are aged 18 years or over, who are healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus. Participants are randomised to receive two intramuscular doses of a full dose (~5×1010 viral particles) of AZD1222 or comparator, meningococcal vaccine MenACWY as first dose and a saline placebo as second dose. Participants have blood samples drawn and clinical assessments for safety as well as immunogenicity at multiple timepoints up to one year post-vaccination. Suspected cases presenting with compatible symptoms were tested for virological confirmation by COVID-19 PCR.
COV005
COV005 is a blinded, multi-centre, randomised, controlled Phase I/II trial assessing the safety, efficacy, and immunogenicity of AZD1222 in 2,070 participants in South Africa. Trial participants are aged 18-65 years, who are living with or without HIV, are randomised to receive two intramuscular doses of AZD1222 at 5-7.5 x1010 viral particles or saline placebo. Participants had blood samples drawn and clinical assessments for safety as well as immunogenicity at multiple timepoints up to one year post-vaccination. Regular COVID-19 PCR testing is performed up to one year post-vaccination.
COVID-19 Vaccine AstraZeneca, formerly AZD1222
COVID-19 Vaccine AstraZeneca was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
In addition to the programme led by Oxford University, AstraZeneca is conducting a large trial in the US and globally. In total, Oxford University and AstraZeneca expect to enrol up to 60,000 participants globally.
The AstraZeneca COVID-19 vaccine has already been granted a conditional marketing authorisation or emergency use in close to 50 countries, spanning four continents including in the EU, a number of Latin American countries, India, Morocco and the UK.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
SOURCE: AstraZeneca
- Digi Communications NV announces investors call for the presentation of Q3 2026 financial results
- USFRA Brings Biofuels Evidence to Europe
- TechPunt nommé distributeur officiel de Zendure aux Pays-Bas
- TechPunt benoemd tot officiële Zendure-distributeur voor Nederland
- How Full-Color 3D Printing Brings LAIKA’s Wildwood Characters to Life
- Sešas pilsētas, trīs gadi, viena kopīga izpēte: kas notiek, kad apvienojas radošās industrijas un aprites ekonomikas prakses?
- Seks byer, tre år, én fælles undersøgelse: Hvad sker der, når kreative brancher og cirkulær økonomi mødes?
- Six villes, trois ans, une exploration commune : que se passe-t-il lorsque les industries créatives et les pratiques de l’économie circulaire se rencontrent ?
- fiskaly enters Czech market with EET 2.0 compliant solution
- Digi Communications N.V. announces exercise of share options by the executive directors of the Company
- BevZero Equipment and Tomsa Destil Announce ClearAlc Dealcoholization Technology Installation at Destilerías San Valero in Spain
- Digi Communications NV announces resolutions of the Extraordinary General Meeting of Shareholders from 15 September 2026
- THIRDREALITY präsentiert Local-First Smart-Home-Ökosystem auf der IFA 2026
- Cold Jet wprowadza na rynek system TEC1200: Czyszczenie suchym lodem wzmocnione termicznie
- A Cold Jet lança o TEC1200, que adiciona potência de limpeza térmica melhorada à limpeza com gelo seco em 2026
- Cold Jet lanza la TEC1200, que añade potencia de limpieza térmicamente mejorada a la limpieza con hielo seco en 2026
- Cold Jet lance le TEC1200 et introduit le nettoyage thermiquement assisté dans le domaine du nettoyage cryogénique en 2026 !
- Cold Jet bringt den TEC1200 auf den Markt und erweitert das Trockeneisstrahlen im Jahr 2026 um thermisch verstärkte Reinigungskraft
- Digi Communications NV announces PDMR Transactions – Grant of Conditional Stock Options to Executive Directors
- Digi Communications NV announces post-stabilisation period notice regarding the Digi Spain shares
- Digi Communications NV announces availability of H1 2026 financial report
- Digi Communications NV announces availability of Digi Spain’s H1 2026 financial results presentation
- THIRDREALITY stellt Smart Plug E3 vor – mit erweiterter Energieintelligenz und zuverlässiger Smart-Home-Leistung
- New Horizon Europe “CIRCULANDIA” project promotes circular food systems, regenerative agriculture and reusable packaging
- Digi Communications NV announces “Investors Call for the presentation of H1 2026 Financial Results”
- Digi Communications N.V. announces convening of the Company’s Extraordinary General Meeting of Shareholders for 15 September 2026
- A1 SolarStore Brings Direct Solar Buying to a European Market Stuck Behind Distributors
- Digi Communications N.V. announces admission to trading of Digi Spain shares
- Digi Communications N.V. announces pricing confirmed and books successfully covered in the initial public offering of Digi Spain shares
- Digi Communications N.V. announces approval and publication of Prospectus regarding the Initial Public Offering of Digi Spain shares
- Digi Communications N.V. announces the pricing of initial public offering regarding the shares of Digi Spain Telecom S.A.U.
- Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2025 financial year
- Digi Communications N.V. announces resolutions of the General Shareholders’ Meeting from 29 June 2026
- Digi Communications N.V. announces status update on the potential Digi Spain Telecom S.A.U. transaction – announcement of intention to float
- FranklinWH Plans European Market Entry With Residential Energy Storage System Designed for European Homes
- Okinawa Suntory Arena Becomes First Venue in Asia to Install ASB GlassFloor
- Digi Communications NV announces the availability of an updated presentation regarding Digi Spain Telecom S.A.U.
- Twilio Voice and AI power innovative Guinness Price Index
- PMI publikuje pierwszy na świecie globalny standard dotyczący wykorzystania AI w pracy projektowej, podczas gdy ramy zarządzania z trudem nadążają za postępem
- PMI pubblica il primo standard globale al mondo sull'intelligenza artificiale nel lavoro di progetto, mentre i quadri normativi faticano a stare al passo
- PMI publica el primer estándar global del mundo para la IA en el trabajo de proyectos, mientras los marcos de gobernanza luchan por seguir el ritmo
- Prime Elements GmbH Receives German Feedstock Registration
- Digi Communications NV announces framework agreement entered into by the Company’s Romanian subsidiary
- AI-POWERED VOICE HEADSET TECHNOLOGY SET TO TRANSFORM STORE OPERATIONS FOR GERMAN RETAILERS
- Digi Communications NV announces decision of the National Authority for Management and Regulation in Communications (ANCOM)
- Digi Communications NV announces 2026 AGM convocation
- Digi Communications NV announces availability of Q1 2026 financial report
- Digi Communications NV announces investors call for the presentation of the Q1 2026 financial results
- Digi Communications N.V. announces an amendment to the 2026 Financial Calendar
- Digi Communications N.V. announces availability of the Romanian-language ESEF version of the 2025 Annual Report
- Digi Communications N.V. announces availability of the non-statutory consolidated financial statements of Digi Romania S.A. for the year ended 31 December 2025
- Digi Communications N.V. announces availability of 2025 Financial report
- Digi Communications N.V. announces 2025 Financial Year dividend proposal
- Gestionar proyectos de IA con confianza: el PMI lanza la certificación PMI-CPMAI en español, que ofrece pasos prácticos para llevar a cabo con éxito proyectos de IA a los profesionales del sector en España
- Digi Communications N.V. announces status update on the potential Digi Spain Telecom S.A.U. transaction
- Digi Communications N.V. announces registration of the financial instruments resulting from the share capital increase
- Orivante Holdings Deploys AI Tools to Broaden Investor Access in Litigation Finance
- Free ICT Europe Warns of “Sovereignty Gap” in Enterprise ICT
- Europeans demand control over their digital identity
- Digi Communications N.V. announces Decision of the Board of Directors regarding the issuance of new shares
- Digi Communications N.V. announces acquisition of a 51% shareholding in Whyfibre Limited
- Digi Communications N.V. announces extraordinary general meeting’s resolution from 20 March 2026, approving the authority of the Board to issue shares on account of the Company’s retained earnings and general reserves and partially amend the Company’s articles of association
- Proteins Mosaic Q: a citizen-science project to gather evidence for a novel 3D protein structural pattern
- Digi Communications N.V. announces Registration with the FSA of the financial instruments resulting from the conversion of 16,974 A shares into an equal number of class B shares
- Digi Communications NV announces update regarding the live stream link for the Capital Markets Day 2026
- Samsung Electronics America selected EYEONIX’s COMMAND for Presentation in the United States
- Digi Communications NV announces Capital Markets Day 2026 Madrid
- Digi Communications N.V. reports preliminary consolidated revenues of 2,2 billion euros in 2025, a 15% year-over-year increase
- Digi Communications N.V. announces the resolution of the Board of Directors to convert class A shares into an equal number of class B shares for the purpose of distribution in accordance with an ongoing stock option plan
- Digi Communications NV announces Investors call for the presentation of the 2025 preliminary financial results
- Digi Communications N.V. announces Capital Markets Day 2026
Editor's pick archive....

